Farallon Capital Management LLC Has $7.11 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Farallon Capital Management LLC lessened its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 25.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 673,000 shares of the company’s stock after selling 225,600 shares during the period. Farallon Capital Management LLC owned 0.09% of Roivant Sciences worth $7,114,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of ROIV. nVerses Capital LLC acquired a new position in Roivant Sciences during the 2nd quarter worth about $34,000. Acadian Asset Management LLC bought a new stake in Roivant Sciences in the first quarter valued at approximately $72,000. Fifth Third Wealth Advisors LLC acquired a new stake in Roivant Sciences during the 2nd quarter valued at approximately $101,000. ORG Partners LLC bought a new stake in shares of Roivant Sciences in the 2nd quarter valued at $106,000. Finally, Capstone Investment Advisors LLC acquired a new stake in shares of Roivant Sciences during the fourth quarter worth $170,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analysts Set New Price Targets

ROIV has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a report on Thursday, September 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Piper Sandler raised their price target on shares of Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Finally, Bank of America lifted their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Roivant Sciences presently has an average rating of “Moderate Buy” and an average price target of $17.39.

Roivant Sciences Trading Down 0.6 %

NASDAQ:ROIV opened at $11.90 on Tuesday. The company has a market cap of $8.79 billion, a PE ratio of 2.35 and a beta of 1.25. Roivant Sciences Ltd. has a one year low of $8.24 and a one year high of $13.24. The firm has a 50-day moving average of $11.47 and a 200-day moving average of $11.06. The company has a debt-to-equity ratio of 0.05, a current ratio of 27.91 and a quick ratio of 27.91.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The company had revenue of $55.10 million during the quarter, compared to the consensus estimate of $30.72 million. During the same quarter in the prior year, the company posted ($0.38) earnings per share. The firm’s revenue for the quarter was up 155.1% on a year-over-year basis. As a group, equities research analysts expect that Roivant Sciences Ltd. will post -1.14 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.